Berodual ®. Prevention and treatment of symptoms in chronic obstructive airway disorders with reversible airflow limitation such as bronchial asthma and. Jun 27, Pulmonary Disease, Chronic Obstructive, Drug: Berodual® Respimat® inhaler Drug: Berodual® metered dose inhaler, Phase 3. Metered Dose Inhaler in Chronic Obstructive Airway Disease fenoterol/ ipratropium bromide combination (Berodual) when inhaled as a dry powder and by. When the solution enters the eye, the pupil dilates, the intraocular pressure increases, which is accompanied by pain click the following article discomfort in the eyeball, an unclear vision of the objects, the appearance of colored spots in front of the eyes and redness of the conjunctiva. Companies A to Z. Max: 8 actuations daily ave: actuations tds. Patients with treated basal cell carcinoma are allowed Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis Patients who have undergone thoracotomy with pulmonary resection. The solution must be used through appropriate inhalers. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study Patients with a recent history i. Drug Images. The above list may be incomplete and please also mention if you experience other symptoms than mentioned above. Labelling requirements only. If you have symptoms of an allergy, such as:. Boehringer Ingelheim.